BTIG Starts NxStage Medical (NXTM) at Buy

BTIG initiated coverage on NxStage Medical (NASDAQ: NXTM) with a Buy rating and a price target of $27.

Analyst Sean Lavin said, "While the home dialysis market has some hurdles, we think NXTM is poised to benefit from the shift to the home setting, potentially better payer mix, and a strong pipeline of new products. NXTM has proven its Centers of Excellence project to some extent and this could lead to the company being taken out. Profitability is also near term."

For an analyst ratings summary and ratings history on NxStage Medical click here. For more ratings news on NxStage Medical click here.

Shares of NxStage Medical closed at $20.15 yesterday.

You May Also Be Interested In

• DA Davidson Starts Napco Security Technologies, Inc. (NSSC) at Buy
• Range Resources (RRC) PT Raised to $41 at Mizuho
• Erste Group Downgrades AMD (AMD) to Hold on valuation "significantly higher than peer group"